Additionally, co-administration of TGT with EGFR inhibitors, STAT3 inhibitors, and VEGFA inhibitors may enhance the anti-osteosarcoma effects of TGT, further inhibiting the development and metastasis of osteosarcoma. This evidence concerns the gene EGFR and osteosarcoma.